BR112022000377A2 - Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r - Google Patents
Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4rInfo
- Publication number
- BR112022000377A2 BR112022000377A2 BR112022000377A BR112022000377A BR112022000377A2 BR 112022000377 A2 BR112022000377 A2 BR 112022000377A2 BR 112022000377 A BR112022000377 A BR 112022000377A BR 112022000377 A BR112022000377 A BR 112022000377A BR 112022000377 A2 BR112022000377 A2 BR 112022000377A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- atopic dermatitis
- antagonist
- administration
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r. a presente invenção refere-se a métodos para o tratamento de dermatite atópica moderada a grave ou grave em um indivíduo pediátrico. em um aspecto, os métodos compreendem a administração ao indivíduo de uma ou mais doses de um antagonista do receptor de interleu-cina-4 (il-4r), como um anticorpo anti-il-4r ou fragmento de ligação ao antígeno do mesmo.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962882946P | 2019-08-05 | 2019-08-05 | |
US201962940108P | 2019-11-25 | 2019-11-25 | |
US202062985715P | 2020-03-05 | 2020-03-05 | |
US202063024467P | 2020-05-13 | 2020-05-13 | |
US202063032408P | 2020-05-29 | 2020-05-29 | |
PCT/US2020/044960 WO2021026205A1 (en) | 2019-08-05 | 2020-08-05 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022000377A2 true BR112022000377A2 (pt) | 2022-05-10 |
Family
ID=72148241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022000377A BR112022000377A2 (pt) | 2019-08-05 | 2020-08-05 | Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210040222A1 (pt) |
EP (1) | EP4010373A1 (pt) |
JP (1) | JP2022543612A (pt) |
KR (1) | KR20220044563A (pt) |
CN (1) | CN114173816A (pt) |
AU (1) | AU2020326713A1 (pt) |
BR (1) | BR112022000377A2 (pt) |
CA (1) | CA3147113A1 (pt) |
IL (1) | IL289930A (pt) |
MX (1) | MX2022001247A (pt) |
SG (1) | SG11202113310UA (pt) |
WO (1) | WO2021026205A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
MX2016011132A (es) | 2014-02-28 | 2016-12-08 | Regeneron Pharma | Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r. |
KR102462039B1 (ko) | 2016-09-01 | 2022-11-02 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법 |
WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
MX2020012064A (es) | 2018-05-13 | 2021-04-13 | Regeneron Pharma | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. |
BR112022000581A2 (pt) | 2019-08-05 | 2022-03-03 | Regeneron Pharma | Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2614260T3 (es) | 2000-05-26 | 2017-05-30 | Immunex Corporation | Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
BRPI0416603A (pt) | 2003-11-07 | 2007-01-30 | Immunex Corp | anticorpo que se liga ao receptor interleucina-4 (il-4) humano |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
MY149079A (en) | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
PL2624865T3 (pl) | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R) |
ES2675779T3 (es) | 2012-09-07 | 2018-07-12 | Regeneron Pharmaceuticals, Inc. | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
WO2018057776A1 (en) * | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
MX2020012064A (es) * | 2018-05-13 | 2021-04-13 | Regeneron Pharma | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. |
-
2020
- 2020-08-05 SG SG11202113310UA patent/SG11202113310UA/en unknown
- 2020-08-05 EP EP20758405.3A patent/EP4010373A1/en active Pending
- 2020-08-05 KR KR1020227007522A patent/KR20220044563A/ko active Search and Examination
- 2020-08-05 CN CN202080054323.2A patent/CN114173816A/zh active Pending
- 2020-08-05 BR BR112022000377A patent/BR112022000377A2/pt unknown
- 2020-08-05 MX MX2022001247A patent/MX2022001247A/es unknown
- 2020-08-05 CA CA3147113A patent/CA3147113A1/en active Pending
- 2020-08-05 WO PCT/US2020/044960 patent/WO2021026205A1/en unknown
- 2020-08-05 AU AU2020326713A patent/AU2020326713A1/en active Pending
- 2020-08-05 JP JP2022507355A patent/JP2022543612A/ja active Pending
- 2020-08-05 US US16/985,708 patent/US20210040222A1/en active Pending
-
2022
- 2022-01-17 IL IL289930A patent/IL289930A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220044563A (ko) | 2022-04-08 |
IL289930A (en) | 2022-03-01 |
US20210040222A1 (en) | 2021-02-11 |
WO2021026205A1 (en) | 2021-02-11 |
SG11202113310UA (en) | 2021-12-30 |
EP4010373A1 (en) | 2022-06-15 |
CN114173816A (zh) | 2022-03-11 |
AU2020326713A1 (en) | 2022-02-17 |
JP2022543612A (ja) | 2022-10-13 |
CA3147113A1 (en) | 2021-02-11 |
MX2022001247A (es) | 2022-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022000377A2 (pt) | Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r | |
AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
PH12017501934A1 (en) | Methods for treating or preventing migraine headache | |
BR112015005048A8 (pt) | métodos para tratar dermatite atópica por administração de antagonista il-4r | |
MX2019012818A (es) | Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos. | |
AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
BR112014008764A8 (pt) | Usos de um anticorpo, anticorpo, composição farmacêutica e combinação para o tratamento de artrite reumatoide | |
BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
MX2016011132A (es) | Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r. | |
AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
BR112022015363A2 (pt) | Uso de um antagonista do receptor de interleucina-4 (il-4r), composição farmacêutica e recipiente para tratar dermatite atópica (da) ou melhorar um parâmetro associado à da em um indivíduo | |
BR112017003571A2 (pt) | terapia combinada | |
BR112016027881A2 (pt) | antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv | |
NZ769607A (en) | Methods for treating atopic dermatitis by administering an il-4r inhibitor | |
BR112017010440A2 (pt) | administração sublingual de riluzol | |
BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
BR112022022235A2 (pt) | Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4r | |
BR112017010423A2 (pt) | formulação sublingual de riluzol | |
BR112019006216A2 (pt) | compostos de p2x3 e/ou p2x2/3 e métodos | |
EA201892438A1 (ru) | 6-АМИНОПИРИДИН-3-ИЛТИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγt | |
MX2019003235A (es) | Metodos para tratar dermatitis atopica severa administrando un inhibidor de receptor de isoleucina-4. | |
BR112017021194A2 (pt) | compostos espirocíclicos | |
BR112015000808A2 (pt) | regime de dosagem para inibidores de janus quinase (jak) |